U.S. Marine and Shipping Stock News

Why CorVel is back on investors’ radar Fresh commentary on CorVel (CRVL) is drawing attention to its 85.4% return on invested capital and debt free balance sheet, raising questions about how this quality profile lines up with the current share price. See our latest analysis for CorVel. CorVel’s recent share price tells a mixed story, with a 13.06% 1 month share price return and a 2.21% 1 day gain contrasting with a 24.74% 3 month share price decline and a 50.65% 1 year total shareholder...

Venture Global (NYSE:VG) has closed an $8.6b project financing for phase 2 of its CP2 LNG project. The company has reached a final investment decision for CP2 Phase 2, described as the largest standalone project financing in the U.S. bank market. Nearly all of the project's capacity is contracted to long term customers in Europe and Asia. For investors watching NYSE:VG, the CP2 Phase 2 financing lands at a time when the stock is trading around $13.1. It has shown a sharp move, up 33.9% over...

Costco Wholesale is facing a nationwide class-action lawsuit seeking customer refunds tied to import tariffs. The case follows a Supreme Court decision that struck down certain Trump-era duties, triggering potential government tariff refunds. Plaintiffs argue Costco must pass any tariff-related recoveries back to members who may have overpaid on imported goods. The dispute focuses on Costco's member-first positioning and could influence how large retailers handle future tariff refunds. For...

If you are wondering whether Target's current share price reflects value or whether you would be paying up for a well known brand, this article walks through what the numbers show. Target's stock recently closed at US$117.34, with returns of 2.4% over 30 days, 16.7% year to date and 17.2% over 1 year, while the 3 year and 5 year returns of 18.0% and 27.6% are weaker. Recent coverage has focused on Target's position in U.S. retail, including its big box store footprint, digital sales...

Snap (SNAP) is rolling out “Cricket in a Snap,” an ad offering built around India’s cricket season. It uses AR formats and real-time chat to link brands with Gen Z fans during high-traffic matches. See our latest analysis for Snap. Despite Snap’s push into experiences like “Cricket in a Snap,” recent trading has been weak, with a 7 day share price return of 11.63% and a year to date share price return decline of 43.91%, while the 5 year total shareholder return decline of 92.19% points to...

Mid-America Apartment Communities (MAA) has been drawing attention after recent share price pressure, with the stock showing negative returns over the past month, past 3 months and year. That slump is prompting closer scrutiny from income-focused REIT investors. See our latest analysis for Mid-America Apartment Communities. The latest share price of US$126.32 leaves Mid-America Apartment Communities with a 7-day share price return of a 4.9% decline and a year-to-date share price return of a...

Earlier this month, Vericel Corporation received U.S. FDA approval to begin commercial manufacturing of its MACI cartilage repair therapy at its new Burlington, Massachusetts cell therapy facility starting in the second quarter of 2026, expanding capacity for symptomatic knee cartilage defect treatment in adults. This manufacturing approval not only supports higher MACI production volumes but also strengthens Vericel’s ability to pursue potential commercialization of the therapy in markets...

In February 2026, Affiliated Managers Group reported fourth quarter and full-year 2025 results showing a 22% year-over-year increase in annual economic earnings per share and outlined plans to expand its global private markets presence through new investments in HighBrook Investors and Garda Capital Partners. By deepening partnerships with independent alternative managers, Affiliated Managers Group is reinforcing its position in higher-fee private markets and broadening its exposure to...

Flutter Entertainment’s latest results showed Q4 revenue of US$4.74 billion, up 24.9% year on year but below analyst forecasts for both revenue and earnings per share. On the same day, the company also launched the fifth tranche of its multi‑year share repurchase program, authorizing Goldman Sachs to buy back up to US$250 million of shares to reduce its share count. We’ll now examine how Flutter’s Q4 earnings miss against analyst expectations reshapes the previously optimistic investment...

Halcyon has integrated its technology with Freddie Mac's Asset and Income Modeler (AIM) to support automated dual source income assessment for self employed borrowers. The solution combines borrower provided tax returns with IRS transcripts, automating data validation for lenders using Freddie Mac loans. The capability is immediately available to approved lenders, allowing faster adoption in current mortgage underwriting workflows. For investors watching Federal Home Loan Mortgage...

On 12 March 2026, Fareway Stores announced it had adopted Instacart’s Storefront Pro platform and joined the Instacart Marketplace with no markups on pickup orders, bringing a unified online and app-based grocery shopping experience to its more than 140 Midwestern locations. The partnership showcases Instacart’s enterprise capabilities, such as AI-powered search, integrated fulfillment, and Carrot Ads retail media, which can deepen retailer relationships and broaden higher-margin technology...

If you are wondering whether Cloudflare's share price still makes sense after its strong run, this article will help you unpack what that current price could imply about the company. Cloudflare's stock last closed at US$212.45, with returns of 8.8% over the past week, 12.2% over the past month, 8.4% year to date and 82.9% over the past year. The 3 year and 5 year returns stand at 289.6% and 196.3% respectively. Recent coverage around Cloudflare has continued to focus on its role in content...

Novo Nordisk and Hims & Hers have resolved their legal dispute and entered into a new distribution partnership. Hims & Hers will move patients from compounded GLP-1 products to Novo Nordisk's branded obesity medicines, including Ozempic and Wegovy. As part of the agreement, Hims & Hers will stop promoting compounded GLP-1 alternatives, and Novo Nordisk will withdraw its lawsuit. The deal broadens digital access to Novo Nordisk's FDA approved therapies and tightens control over prescription...

Earlier this month, Hagerty’s Broad Arrow Auctions division set a company and event record at The Amelia Concours, generating over US$111,000,000 in total sales during the 31st running of the classic car celebration. The record auction performance underscores Hagerty’s expanding role in the collector car ecosystem, reinforcing how event-driven services can complement its core insurance and enthusiast offerings. We’ll now examine how Broad Arrow’s record auction sales might influence...

If you are trying to work out whether Ocular Therapeutix at around US$8.76 is a bargain or just fairly priced, starting with a clear view of its valuation can help frame your next move. The stock has seen mixed returns, with a 14.7% decline over the last 7 days and a 4.4% decline over the last 30 days, while the 1 year return sits at 13.5% and the 3 year return at 76.6%, compared with a 57.6% decline over 5 years. Recent market attention on Ocular Therapeutix has focused on its progress as...

Brown-Forman (BF.B) is back in focus after Bernstein cut its rating, citing ongoing margin pressure from higher barrelled whisky costs and softer demand, even though recent quarterly results came in ahead of expectations. See our latest analysis for Brown-Forman. At a share price of $23.49, Brown-Forman has seen momentum fade, with a 30 day share price return of 22.42% and a 90 day share price return of 23.63%. The 5 year total shareholder return of 62.11% highlights how prolonged the...

How BioMarin Pharmaceutical’s Recent Moves Set Up a Closer Look at Value Before we get into the numbers, if you are wondering whether BioMarin Pharmaceutical’s current share price fairly reflects its long term potential, it helps to first step back and see what the market has been doing with the stock lately. BioMarin’s share price closed at US$58.51 most recently, with returns of 4.3% decline over the past week, 3.0% decline over the past month, a 1.6% decline year to date, and a 15.7%...

Investor sentiment toward Concentrix (CNXC) came under pressure as escalating geopolitical tensions triggered a broad risk off move, pulling down business process outsourcing and consulting stocks alongside the wider sector. See our latest analysis for Concentrix. At a recent share price of US$31.67, Concentrix has seen a 7 day share price return of about a 10% decline and a year to date share price return of roughly a 23% decline. The 1 year total shareholder return of around a 28% decline...

Adobe reported first-quarter 2026 results with revenue of US$6.40 billion and net income of US$1.89 billion, while also issuing second-quarter guidance and confirming a leadership transition as long‑time CEO Shantanu Narayen plans to step down once a successor is appointed. Beyond the headline earnings beat, the combination of Narayen’s planned departure, an extensive share repurchase program, and growing AI‑related partnerships such as the expanded Major League Baseball deal is reshaping...

Capital Clean Energy Carriers Corp. recently reported fourth-quarter 2025 sales of US$98.35 million and full-year sales of US$392.71 million, alongside appointing veteran energy executive Martin Houston as Chairman and moving Keith Forman to Vice-Chairman. The combination of higher annual sales and earnings per share from continuing operations with Houston’s extensive global energy leadership experience could meaningfully influence how investors assess the company’s long-term...

Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy at the 2026 MDA Clinical and Scientific Conference, showing multi-year stabilization of patient function and a favorable safety profile in a disease with no approved therapies. An unusually high 99% of eligible participants from earlier sevasemten trials chose to continue into the MESA extension, underscoring sustained engagement with the investigational...

Executive change at HF Sinclair HF Sinclair (DINO) has appointed Mr. Vivek Garg as acting Chief Financial Officer, a move that puts fresh attention on leadership stability and financial oversight for investors tracking the stock. See our latest analysis for HF Sinclair. HF Sinclair’s 1-day share price return of a 2.72% decline and 1-month share price return of a 5.16% decline sit against a stronger 90-day gain of 12.84% and 1-year total shareholder return of 79.84%. This contrast highlights...

Merchants Bancorp (MBIN) is back in focus after its latest earnings report showed revenues, EPS, and net interest income all ahead of analyst estimates, highlighting its low-risk, government-backed lending model. See our latest analysis for Merchants Bancorp. The latest earnings beat comes after a mixed price pattern, with a 10.52% 1 month share price decline, a 14.99% 3 month share price return, and a 25.56% year to date share price return, alongside a 63.14% 3 year total shareholder return...

Market shock around LNG flows puts Golar LNG in focus A conflict driven closure of shipping routes in the Strait of Hormuz has disrupted roughly 19% of global LNG exports, injecting fresh volatility into gas markets and pulling Golar LNG (GLNG) into sharper investor focus. See our latest analysis for Golar LNG. The LNG route disruption comes after a choppy few weeks for Golar LNG, with a 1-day share price return of a 4.13% decline and a 7-day share price return of an 8.79% decline. However, a...